Johnson & Johnson Option Alert: Jun 20 $150 Calls at the Ask: 750 vs 2438 OI

Johnson & Johnson Option Alert: Jun 20 $150 Calls at the Ask: 750 @ $7.45 vs 2438 OI; Ref=$155.22

Johnson & Johnson Option Alert: Jun 20 $150 Calls at the Ask: 750 @ $7.4 vs 2438 OI; Ref=$155.145

Johnson & Johnson Option Alert: Jun 20 $150 Calls at the Ask: 750 @ $7.35 vs 2438 OI; Ref=$155.055

Johnson & Johnson Option Alert: Jun 20 $150 Calls at the Ask: 750 @ $7.3 vs 2438 OI; Ref=$154.95

Johnson & Johnson (NYSE:JNJ) Bolsa

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

manufacturing PMI

Long Ideas

Trading Ideas

AAPL

NVDA

Apple, Nvidia, TSMC y otras grandes empresas están trayendo su producción de vuelta a EE. UU. en una nueva ola de relocalización.

Gigantes tecnológicos y fabricantes de EE. UU. apuestan por relocalizar su producción: ¿Vuelve el &#34;Made in USA&#34;?

Jim Cramer

Equities

Markets

ABBV

Jim Cramer advierte que el aumento de los rendimientos del Tesoro hace que los bonos sean más atractivos que las acciones defensivas.

Jim Cramer: Por qué los bonos son más seguros que las acciones defensivas

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Health Care

AMGN

REGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Analysts' ratings for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.33, with a high estimate of $181.00 and a low estimate of $153.00. This current average has decreased by 0.44% from the previous average price target of $170.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1749150069_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Johnson &amp; Johnson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$153.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$164.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$164.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Johnson &amp; Johnson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Unveiling the Story Behind Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Johnson &amp; Johnson's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 2.39%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Johnson &amp; Johnson's net margin is impressive, surpassing industry averages. With a net margin of 50.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 14.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Johnson &amp; Johnson's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.89% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

12 Analysts Have This To Say About Johnson & Johnson

Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) on Thursday collaborated with Dr. Reddy's Laboratories Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45788813/alvotech-and-dr-reddys-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-keytruda-pem" rel="noreferrer noopener">for global markets</a>.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) is indicated for numerous cancer types.
Keytruda's worldwide sales were $29.5 billion in 2024. The collaboration combines Dr. Reddy's and Alvotech's capabilities in biosimilars, speeding up the development process and extending the global reach for this biosimilar candidate.
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
Subject to certain exceptions, each party will have the right to commercialize the product globally.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In March, Alvotech&nbsp;announced the acquisition of&nbsp;R&amp;D operations of&nbsp;Xbrane Biopharma AB along with a biosimilar candidate, XB003, which is based on Cimzia (certolizumab pegol)&nbsp;for <a target="_blank" href="https://www.benzinga.com/news/mid-cap/25/03/44412592/alvotech-strengthens-biosimilar-portfolio-with-27-million-xbrane-rd-deal" rel="noreferrer noopener">around SEK275 million</a> (around $27 million).
The transaction includes a cash payment of SEK102.2 million at closing, along with the assumption of SEK172.8 million in debt and accounts payable.
HSBC upgraded Dr Reddy's Laboratories from Hold to Buy and raised the price <a target="_blank" href="https://www.benzinga.com/quote/RDY/analyst-ratings" rel="noreferrer noopener">forecast from $14.44 to $16.9</a>.
<h2 class="wp-block-heading">Stock Prediction For 2025 For Alvotech</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Alvotech, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Alvotech, the 200-day moving average sits at $11.44, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is above the current price of $10.46. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: At the last check on Thursday, RDY stock was up 6.07% at $15.65, and ALVO stock was down 2.49% at $10.56.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" target="_blank" rel="noreferrer noopener">Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug</a></li>
</ul>
Photo by T. Schneider via Shutterstock

News

Contracts

Movers

General

ALVO

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $181 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Upgrades

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) shared data from several <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer studies</a> at the 2025 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday.
Here&#8217;s that the New Brunswick, New Jersey-based company released.
<h3 class="wp-block-heading">Phase 3 AMPLITUDE Study</h3>
Johnson &amp; Johnson released promising Phase 3 results from the AMPLITUDE study evaluating niraparib combined with abiraterone acetate plus prednisone (AAP) in metastatic castration-sensitive prostate cancer (mCSPC) patients with homologous recombination repair (HRR) genetic alterations, including BRCA mutations.
Key findings:
<ul class="wp-block-list">
<li>The study met its primary endpoint of radiographic progression-free survival (rPFS) among 696 patients.</li>
<li>Patients with BRCA mutations (n=191) saw the strongest benefit: 
<ul class="wp-block-list">
<li>Median rPFS was not reached vs. 26 months for placebo group</li>
<li>48% reduced risk of radiographic progression or death</li>
</ul>
</li>
<li>All HRR-altered patients also benefited: 
<ul class="wp-block-list">
<li>Median rPFS not reached vs. 29.5 months for placebo</li>
<li>37% reduced risk of progression or death</li>
</ul>
</li>
<li>Symptomatic progression was significantly reduced: 
<ul class="wp-block-list">
<li>56% reduction in BRCA patients</li>
<li>50% reduction in HRR patients</li>
</ul>
</li>
<li>Early overall survival (OS) data shows a positive trend: 
<ul class="wp-block-list">
<li>25% reduced risk of death in BRCA patients</li>
<li>21% reduction in HRR patients</li>
<li>OS data still maturing</li>
</ul>
</li>
</ul>
In summary, the combination therapy significantly delays disease progression and shows encouraging early signs of extending survival in genetically selected mCSPC patients.
<h3 class="wp-block-heading">JNJ-79635322 Phase 1 Study</h3>
Johnson &amp; Johnson released initial Phase 1 results of JNJ-79635322 for relapsed or refractory multiple myeloma.
The overall response rate (ORR) among the 36 patients who received the recommended phase 2 dose (RP2D) was 86.1%. In the 27 patients who were naive to BCMA and GPRC5D-directed therapies, the ORR <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749276/early-results-from-johnson-johnsons-trispecific-antibody-show-promising-response-in-heavily-pretre" rel="noreferrer noopener">was 100% at the RP2D</a>.
<h3 class="wp-block-heading">Phase&nbsp;1b/2 CARTITUDE-1 Study</h3>
The company&nbsp;also revealed new long-term follow-up data from the Phase&nbsp;1b/2 CARTITUDE-1 study demonstrating 33% (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&nbsp;(ciltacabtagene autoleucel; cilta-cel) achieved PFS of five years or more with a single infusion and no maintenance or subsequent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749277/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-lasting-treatment-free-remissions-" rel="noreferrer noopener">anti-myeloma therapy</a>.
A subset of 12 patients who underwent serial evaluations at a single site remained minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up.
At a median follow-up of 61.3 months, the median OS was 60.7 months.
With longer follow-up, the safety profile in CARTITUDE-1 was consistent with the known safety profile of CARVYKTI, with no new safety signals observed.
There were two newly reported second primary malignancies (both solid tumors) and no new Parkinsonism events or cranial nerve palsies.
<h3 class="wp-block-heading">Phase 3 PERSEUS and Phase 3 CEPHEUS Studies</h3>
Johnson &amp; Johnson&nbsp;highlighted data from two studies of DARZALEX&nbsp;FASPRO (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained MRD negativity rates and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749281/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-regimen-shows-95-percent-progression-free" rel="noreferrer noopener">regardless of transplant status</a>.
<h3 class="wp-block-heading">Phase 3 PERSEUS Study</h3>
New analysis from the Phase 3 PERSEUS study shows the addition of DARZALEX&nbsp;FASPRO to bortezomib, lenalidomide and dexamethasone (D-VRd), followed by an investigational maintenance regimen of DARZALEX&nbsp;FASPRO with lenalidomide (D-R), led to improved and deepened rates of overall and sustained MRD negativity, defined as no cancer cells detected within 100,000 bone marrow cells for at least 24 months, compared to VRd induction and consolidation with R maintenance.
More than half of patients who received the DARZALEX&nbsp;FASPRO-based regimen achieved sustained MRD negativity for 24 or more months, and more than two-thirds of patients achieved sustained MRD negativity at 12 months, showing 95.3% PFS at 48 months.
<h3 class="wp-block-heading">Phase 3 CEPHEUS Study</h3>
The post-hoc analysis of the Phase 3 CEPHEUS study focused exclusively on transplant-ineligible patients, showing that DARZALEX&nbsp;FASPROto VRd significantly deepens response and prolongs PFS compared to VRd alone.
Data from the Phase 3 CEPHEUS study show 60% overall MRD negativity and improved PFS with DARZALEX FASPRO&nbsp;in transplant-ineligible newly diagnosed patients.
Price Action: JNJ stock is down 0.62% at $154.40 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45745671/ferguson-stock-soars-on-strong-q3-growth-margin-gains-and-upbeat-guidance" target="_blank" rel="noreferrer noopener">Ferguson Stock Soars On Strong Q3 Growth, Margin Gains And Upbeat Guidance</a></li>
</ul>
Image: Shutterstock

Large Cap

Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI&#xAE;&nbsp;remain progression-free
CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment
CHICAGO, June 3, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson &amp; Johnson's dedication to advancing transformative therapies that aim to reshape the treatment landscape for patients with multiple myeloma.
In a subset of 12 patients who underwent serial evaluations at a single site, all were minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up. Findings were featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7507). The data were also simultaneously published in The Journal of Clinical Oncology.

Johnson & Johnson Says New Long-Term CARTITUDE-1 Data Show One-Third Of Patients Treated With CARVYKTI Remain Progression-Free

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO&#xAE;&nbsp;for 24 months or longer in the Phase 3 PERSEUS study
Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO&#xAE; in transplant-ineligible newly diagnosed patients
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced data from two studies highlighting that a DARZALEX FASPRO&#xAE; (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2,3 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study (Abstract #7501) and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (Abstract #7516) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Johnson & Johnson Announces Data From Two Studies Highlighting That DARZALEX FASPRO-Based Quadruplet Regimen Demonstrated Deep And Sustained MRD Negativity Rates, And Improved Long-Term PFS In NDMM Patients

Phase 1 trial demonstrates encouraging clinical activity of investigational&nbsp;immunotherapy for relapsed or refractory multiple myeloma
Novel investigational dual-antigen-targeting&nbsp;immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells&nbsp;
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. In the 27 patients who were naive to BCMA and GPRC5D directed therapies, the ORR was 100 percent at the RP2D. Findings were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=1437573614&amp;u=https%3A%2F%2Fmeetings.asco.org%2Fmeetings%2F2025-asco-annual-%2520meeting%2F327%2Fprogram-guide%2Fscheduled-sessions&amp;a=2025+American+Society+of+Clinical+Oncology+(ASCO)+Annual+Meeting">2025 American Society of Clinical Oncology (ASCO) Annual Meeting</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2239716214&amp;u=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2FABSTRACT489908&amp;a=7505">7505</a>). The study will also be featured as one of the six best abstracts during the Plenary Abstracts Session at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2405979170&amp;u=https%3A%2F%2Fehaweb.org%2Fcongress%2Feha2025-congress%2F&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=3428041764&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159177%2Frakesh.popat.first-in-human.study.of.jnj-79635322.28jnj-532229.a.novel.html%3Ff%3Dmenu%253D6%252Abrowseby%253D8%252Asortby%253D2%252Amedia%253D3%252Ace_id%253D2882%252Amarker%253D5848%252Afeatured%253D19595&amp;a=S100">S100</a>).

Johnson & Johnson Announces Initial Phase 1 Results Of JNJ-79635322, Investigational TsAb In Patients With Relapsed Or Refractory Multiple Myeloma

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA&#xAE; (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms
Data show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of care
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) genetic alterations including BRCA. The results show a clinically meaningful and statistically significant improvement in both radiographic progression-free survival (rPFS) and time to symptomatic progression (TSP), with an early trend toward improved overall survival (OS)—highlighting the potential of the combination in this patient population to delay both cancer progression and the worsening of symptoms.1&nbsp;This marks the first Phase 3 data to show clinical improvement with a PARP-based combination in mCSPC. The findings are being presented as a late-breaking oral presentation (Abstract #LBA5006) at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440391-1&amp;h=786988511&amp;u=https%3A%2F%2Fmeetings.asco.org%2Fmeetings%2F2025-asco-annual-%2520meeting%2F327%2Fprogram-guide%2Fscheduled-sessions&amp;a=2025+American+Society+of+Clinical+Oncology+Annual+Meeting">2025 American Society of Clinical Oncology Annual Meeting</a>. The data have also been selected for Best of ASCO and included in the ASCO Press Program.

Johnson & Johnson's AKEEGA Combo Shows Nearly 50% Reduction In Disease Progression For BRCA-Altered Prostate Cancer In Phase 3 AMPLITUDE Study

In the current market session, Johnson &amp; Johnson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) share price is at $153.53, after a 0.19% increase. Moreover, over the past month, the stock decreased by 1.78%, but in the past year, went up by 5.68%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1748440851_0.png" alt="Past Year Chart" />

<h3>A Look at Johnson &amp; Johnson P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Johnson &amp; Johnson has a lower P/E than the aggregate P/E of 25.34 of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748440851_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Johnson & Johnson

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">lymphopoietin) and IL-13</a>.
Teva has an exclusive license to develop BD9 for TH2-driven inflammatory diseases such as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45615937/teva-and-biolojic-design-initiate-ind-enabling-studies-of-bd9-a-multibody-designed-to-explore-the-" rel="noreferrer noopener">atopic dermatitis and asthma</a>.&nbsp;
By simultaneously blocking two key drivers of TH2-driven inflammation, BD9 can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma, where current treatments fall short.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The initiation of IND-enabling studies marks a critical milestone in translating this scientific innovation into a potential therapeutic option. It will pave the way for clinical trials and ultimately bring hope to underserved patient populations.
Under the terms of their agreement, Teva is developing BD9 worldwide.
In exchange, Biolojic is eligible to receive milestone payments based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones, including the initiation of IND-enabling studies.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In January, The U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of anaphylaxis, a rare but severe allergic reaction associated with glatiramer acetate, a medication used to treat relapsing <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43174108/fda-warns-of-severe-allergic-reaction-risk-with-tevas-multiple-sclerosis-drug" rel="noreferrer noopener">forms of multiple sclerosis (MS)</a>.
Glatiramer acetate, sold under the brand name Copaxone by&nbsp;Teva and as generics like Glatopa, is an injectable medication designed to reduce the frequency of MS relapses.
In February, Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) signed a settlement agreement with&nbsp;Teva Pharmaceuticals.
The settlement resolves all patent litigation related to Axsome's Auvelity (dextromethorphan HBr –&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">bupropion HCl) product</a>.
Auvelity is approved in the U.S. for major depressive disorder.
The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Auvelity in the U.S. before the expiration of applicable Axsome patents.
Price Action: TEVA stock is up 6.01% at $17.98 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>
Photo via Shutterstock

AXSM

TEVA

Why Is Teva Stock Trading Higher On Tuesday?

Activist investor&nbsp;Dan&nbsp;Loeb‘s&nbsp;Third Point LLC&nbsp;acquired a significant stake in consumer health company&nbsp;Kenvue Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/dan-loeb" rel="noreferrer noopener">in the first quarter of 2025</a>.
Kenvue was formerly a part of&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) before becoming an independent&nbsp;<a href="https://www.benzinga.com/news/large-cap/24/08/40659011/johnson-johnson-spin-off-kenvue-wins-lawsuit-over-pain-killer-tylenol-rapid-release-gelcaps" target="_blank" rel="noreferrer noopener">company in August 2023</a>.
The company&#8217;s major products include several J&amp;J brands, including Tylenol, <a href="https://www.benzinga.com/news/large-cap/23/05/32205951/kenvues-ipo-extravaganza-a-historic-41-billion-spinoff-from-johnson-johnson">Listerine, Neutrogena, and Nicorette</a>.&nbsp;
According to recent 13F filings, reflecting his holding as of March 31, 2025, Loeb bought an 8.9 million stake in the company, thereby placing it <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/05/45472025/loebs-third-point-exits-meta-tesla-rotates-into-staples-telecom-industrials" rel="noreferrer noopener">among his top five holdings</a>.
Let's have a look at the company&#8217;s major events.
<ul class="wp-block-list">
<li>On May 8, the company reported first-quarter 2025 sales of $3.74 billion, beating <a href="https://www.benzinga.com/general/health-care/25/05/45297027/neutrogena-maker-kenvue-beats-profit-forecast-ups-sales-outlook" target="_blank" rel="noreferrer noopener">the&nbsp;consensus of $3.68 billion</a>.</li>
<li>Kenvue updated its fiscal 2025 outlook to reflect current foreign exchange rates and the estimated impact of <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">higher costs due to tariffs</a>.&nbsp;</li>
<li>The company now expects a net sales increase of +1% to +3% (-1% to +1% prior) year-over-year, with organic sales growth of +2% to +4 (unchanged) and a ~1% headwind from foreign currency translation <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">(earlier expected around 3%)</a>.</li>
<li>Also, Kenvue appointed Amit Banati as the company's CFO, effective May 12. Banati will <a href="https://www.benzinga.com/pressreleases/25/05/b45280347/kenvue-announces-chief-financial-officer-transition" target="_blank" rel="noreferrer noopener">succeed Paul Ruh</a>.</li>
<li>On April 16, Kenvue announced a five-year collaboration with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to establish a strong foundation for transforming digital operations through advanced&nbsp;<a href="https://www.benzinga.com/pressreleases/25/04/b44834009/kenvue-announces-5-year-collaboration-with-microsoft-to-transform-digital-operations" target="_blank" rel="noreferrer noopener">Artificial Intelligence (AI) technologies</a>.</li>
<li>Kenvue shares rose nearly 11.5% year to date, compared to the&nbsp;Renaissance IPO ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPO#NYSE">IPO</a>), which fell about 1.36%&nbsp;over the same time frame.</li>
<li>The company&#8217;s shares also fared well compared to its closest peer, Estee Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>), which declined 15.06% year to date.</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45528489/loebs-third-point-boosts-apollo-stake-275-soho-house-121-in-q1-bet" target="_blank" rel="noreferrer noopener">Loeb&#8217;s Third Point Boosts Apollo Stake 275%, Soho House 121% In Q1 Bet</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

KVUE

MSFT

Why Dan Loeb Just Made Kenvue One Of His Top Holdings

Everybody "knows" that value investing doesn't work anymore. It's in all the headlines.
Investing today is about technology, everyone says. It's about artificial intelligence. It's about quantum computing, about the rebirth of nuclear energy.
Some of this is true, some isn't, but what's really not true is that value investing doesn't work. In fact, it still works better than just about any other investing approach.
The reason people say otherwise is because they've got value all wrong. "Value," they think, is just another word for "cheap." But most cheap stocks are cheap because they're bad investments.
Here's how to invest in value the right way using just two metrics – and beat the markets handily.
<h2 class="wp-block-heading">What People Get Wrong About Value</h2>
There are a couple of problems with the way people define value investing. First, we need to address the fact that the sound of it is boring.  Value investing sounds like a professor with tweed elbow patches smoking a pipe in an old dusty office in some brick and ivy university somewhere up in Vermont or Maine during a snowstorm. It just sounds boring.
Perhaps if we could call it vulture investing, market pillaging, or some other equally interesting name, it would attract more attention.
But then again, since we seem to have a corner on it, do we really want to attract all that much attention?
Second, let's talk about the way people track value. For instance, the Russell Value Index is supposed to represent value. When you compare it, growth has outperformed value for several hundred consecutive years, according to the literature.
That may be a slight exaggeration, but you get the point.
When you examine the Russell 1000 Value index, it's allegedly the bottom half of the Russell 2000 weighted by value components.
The top holdings include Berkshire Hathaway, Cisco Systems, McDonald&#8217;s, Walt Disney, Raytheon, and Caterpillar. These are all great companies.
What they are not is value companies.
<h2 class="wp-block-heading">The Truth About Value</h2>
When we really look at the hard data, the truth is that absolute value never stopped working. When you look at companies that are trading at discounts to asset value, low multiples of the cash produced by the business, and low multiples of liquidation value, which is still one of my favorites, the truth is that they have continued to work and work very well.
The key thing that most people leave out is they will run a list of companies trading below book value and will say, &#8220;Look, these underperformed the market.&#8221; That is, in fact, true.
More than half of those companies are unprofitable and overleveraged, and their products are going completely out of style. You know, they are CD-ROM manufacturers or buggy whip makers in the business of making something we are never going to use again.
Many of the companies that trade below book value, in all honesty, do so for a reason. They are headed for the garbage pile.
<h2 class="wp-block-heading">Making Value Work: Financial Strength</h2>
How do we get rid of those? You have to adjust for a couple of factors:
<ul class="wp-block-list">
<li>You want strength in the financial statements.</li>
<li>You want the ability to survive, and you prefer that they are profitable.</li>
</ul>
Two papers, with several follow-ups, have come out in the last twenty-five years that show us how to do this.
One of these is Joseph Piotrowski&#8217;s publication &#8220;Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers.&#8221; The F-score is based on that paper.
Value plus the F-score crush the market. When we add value plus the F-score plus credit scores, I prefer the Altman Z score—then you annihilate the market.
The key variable here is profitability and financial strength.
<h2 class="wp-block-heading">The Missing Factor: Profitability</h2>
The other paper, which very few people seem to have read, is important.
In 2013, an economist, Robert Novy-Marks, published a paper that should have but didn&#8217;t redefine the entire playing field for investing. It is called &#8220;The Other Side of Value: The Gross Profitability Premium.&#8221;
Basically, they found that highly profitable companies outperform, no matter how cheap or expensive they may look. It is a single idea that gross profitability is the missing dimension, the missing factor.
It has found its way into some of the academic models. Novy-Marksed followed up on it with &#8220;Profitability Retrospective: What Have We Learned?&#8221;
This is key because many people today will tell you that quality matters. We have got to buy these quality companies. Everyone has a 16, 17, or 18-factor model that supposedly helps us identify truly high-quality companies.
Novy-Marks has found in both the original 2013 study and the retrospective today that you only need one factor to identify quality. That factor is profitability, which is defined in the original paper as gross profits as a percentage of assets.
The higher that is, the better the company is.
<h2 class="wp-block-heading">Quality Simplified</h2>
It explains all of the excess returns from so-called quality investing. When you ask what exactly we are looking for here, it turns out it all boils down to one simple measure.
You can use an 18-factor model, or you can use just gross profitability as a percent of assets. When you look at the largest cap companies that are in the upper end of the range: Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), MasterCard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), UnitedHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), T-Mobile (NASDAQ: TMUS) &#8211; all of the same companies that would show up if we use that super sophisticated, 18-factor quality model for which you will pay a massive premium to have access to the data – it turns out you can get the same list using just gross profitability.
Gross profitability also explains all of the defensive strategies.
All of the defensive low beta stocks are just highly profitable companies that also are growing their asset base slowly. They are doing very conservative investing. They are not de-worsifying the business. They are not trying to grow at a high rate.
They are just ridiculously profitable companies that are willing to sit in place and do what they are good at and continually pile up profits and cash.
<h2 class="wp-block-heading">Unifying Factor</h2>
Profitability explains quality. It explains the low beta and low volatility phenomena.
Many investors have looked for new ways to define value. Cash flow to price, earnings forecast, intangible adjusted tangible book value, adjust for a lot of different factors in R&amp;D. These are going to "fix" value's alleged shortcomings in a day and age of high technology.
The truth is that all these newer value strategies sneak in profitability as a factor in addition to value. Profitability by itself delivers market-beating returns.
Profitability plus value, whether that is price to book or a different model that works, like enterprise value to earnings before interest and taxes, beats the market even more.
<h2 class="wp-block-heading">Why Value Appears to Have Underperformed</h2>
When we look at the underperformance of "value" since 2007, the truth is that it's because we junked up the value universe. We put a lot of garbage in there. There are many stocks trading below book value that are biotech startup companies. They are below the cash balance on the balance sheet, but they are burning cash at a rapid rate and will soon be out of money. The book value will, in fact, disappear.
There are all these companies that look cheap but are wildly unprofitable. They are burning through money.
Then you have a lot of garbage that came in through the two SPAC movements in 2007 and then again in 2020 when companies that were still basically at the garage stage of existence suddenly went public.
We really junked up the value universe with a lot of garbage.
<h2 class="wp-block-heading">The Foundation of Investment Success</h2>
Profitability is not just another factor but another tool.
It is a foundational tool that unifies multiple styles. It is part of quality, defensive value, and even some growth stocks.
Profitability explains a lot of the strategies that people use without relying on complicated, expensive 18-factor models.
If we take low-volatility companies and buy the most profitable, we are going to outperform the market.
If we just buy the most profitable companies, we are going to outperform the market.
If we buy the most profitable companies that are trading at low multiples of the cash produced by the business, we are going to absolutely crush the markets.
This is not a day trading system or a short-term trading system. It is the single best way to build long-term portfolios that beat the market and produce lasting wealth.
<h2 class="wp-block-heading">The Unified Theory of Investing</h2>
Profitability explains almost everything that happens in the market. If you have a great business, it is wildly profitable.
If you are a quality company with high returns on equity, low leverage, and earning stability, you are a very profitable company.
If you are a defensive company with low volatility and lower beta, all of the outperformance of these strategies is because they are profitable companies that are not reinvesting in the business to rapidly grow the asset base.
You have low-investment, profitable companies. There is your entire defensive strategy.
The underperformance of value investing over the last fifteen years or so is entirely because of the addition of so many unprofitable companies. If we use F-scores and profitability to screen out just the profitable undervalued companies, performance goes through the roof.
<h2 class="wp-block-heading">The Simple Path to Success</h2>
Most people won't do it because it doesn't make you rich by next Tuesday. It is not the absolute most exciting strategy on the planet. What it does is give you a very easy, quick way to uncover opportunities.
Two scores.
That is all you have to check. You can put together a universe of companies that can crush the market.
Basically, no folks, value investing is not dead.
If anything, if you understand that financial strength and profitability are the key to making value investing go from boring to the most exciting thing you can possibly do with your money, value investing is very much alive and still very successful.
<h2 class="wp-block-heading">Want to Trade the Next Reversal? Start Here</h2>
Matt Maley is watching one ultra-liquid ETF that surges when the market pulls back. He's used it time and time again—and this Wednesday at 6 PM ET, he'll be live to show you how to time it with precision. It's perfect for short-term traders looking to get ahead of the next move. Register <a href="https://events2.benzinga.com/matt-maley-webinar-wed-may28-2025-registration/?utm_campaign=webinar052825&amp;utm_adType=sponsorad&amp;utm_ad=RD052725">HERE</a> for this free masterclass now.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

AMZN

GOOGL

ORCL

TMUS

Value Investing Is Not Dead - It Just Got Smarter

<a href="https://www.wsj.com/politics/policy/rfk-jr-maha-commission-report-5c13696d">https://www.wsj.com/politics/policy/rfk-jr-maha-commission-report-5c13696d</a>

BNTX

MRNA

NVAX

'What's Inside RFK Jr.'s MAHA Report'- Wall Street Journal

ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study
If approved, DARZALEX FASPRO&#xAE; would be the first treatment to potentially delay or prevent progression to multiple myeloma

Reported Earlier, J&J's DARZALEX FASPRO Wins US FDA Oncologic Drugs Advisory Committee Backing For Early Intervention In HR-SMM, Potentially Preventing Disease Progression

Silicon Valley giants and at least one iconic Detroit auto manufacturer are gearing up for a corporate homecoming—<a href="https://www.benzinga.com/news/management/25/04/44597023/trumps-tariffs-could-spark-reshoring-boom-for-these-4-us-stocks">or so they say</a>.
According to Charles Schwab Chief Investment Strategist Liz Ann Sonders, citing Bloomberg data, talk of "reshoring" among S&amp;P 500 and Russell 3000 companies is hitting &#8220;unprecedented&#8221; levels.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Per ⁦<a href="https://twitter.com/Bloomberg?ref_src=twsrc%5Etfw">@Bloomberg</a>⁩ <a href="https://twitter.com/economics?ref_src=twsrc%5Etfw">@Economics</a>, companies in the S&amp;P 500 and Russell 3000 are talking about "reshoring" at an unprecedented scale <a href="https://t.co/HpIYhlyuUw">pic.twitter.com/HpIYhlyuUw</a>
&mdash; Liz Ann Sonders (@LizAnnSonders) <a href="https://twitter.com/LizAnnSonders/status/1924786017220841822?ref_src=twsrc%5Etfw">May 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses</a>
<h2 class="wp-block-heading">Apple</h2>
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) plans to spend <a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech">$500 billion on U.S. manufacturing</a> and infrastructure. But the iPhone maker has tried this before. 
Back in 2013, under the Obama administration, Apple CEO Tim Cook announced that the Mac Pro would be manufactured in Austin, Texas with components made domestically as part of a $100 million &#8220;Made-in-the-USA&#8221; pitch.
See below. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We have begun manufacturing the Mac Pro in Austin. It's the most powerful Mac ever. Orders start tomorrow. <a href="http://t.co/Jrd1Gic3Ya">pic.twitter.com/Jrd1Gic3Ya</a>
&mdash; Tim Cook (@tim_cook) <a href="https://twitter.com/tim_cook/status/413335029264429056?ref_src=twsrc%5Etfw">December 18, 2013</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
It didn&#8217;t last long. By 2019, under the first Trump administration, Apple <a href="https://www.wsj.com/articles/apple-moves-mac-pro-production-to-china-11561728769">moved</a> production back to China, underscoring its dependence on the highly trained, low-cost workforce and massive infrastructure.
<h2 class="wp-block-heading">Nvidia</h2>
Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang recently <a href="https://www.ft.com/content/3fd3a717-2fbf-42ef-bb08-5baecdeb1985">told the Financial Times</a> that the goal is to procure &#8220;half a trillion dollars worth of electronics in total&#8221; and manufacture &#8220;several hundred billion of it&#8221; <a href="https://www.benzinga.com/25/04/44799936/nvidia-to-build-500b-ai-infrastructure-in-us-in-the-next-four-years-details">in the U.S.</a>
The initiative includes AI chip facilities and supercomputing infrastructure—fueled by supply chain worries, tariffs, and the AI arms race.
In April, Nvidia had already started producing its Blackwell AI GPUs at a Taiwan Semiconductor Manufacturing Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) plant in Phoenix, Arizona. 
Talks for that initiative reportedly <a href="https://www.reuters.com/technology/tsmc-talks-with-nvidia-ai-chip-production-arizona-sources-say-2024-12-05/">began</a> in 2024. 
<h2 class="wp-block-heading">TSMC</h2>
Meanwhile, Taiwan Semiconductor Manufacturing is also planning to double down in Arizona and intends to spend $100 billion more on domestic chip fabs. 
The chipmaker promised to manufacture semiconductors in the U.S. thanks partly to Biden-era incentives. Last year, TSMC chief executive C.C. Wei expressed support for the CHIPS and Science Act, which provides incentives for semiconductor manufacturing in the U.S. 
In March, it announced plans to spend <a href="https://www.benzinga.com/25/03/44103610/taiwan-semiconductor-doubles-down-on-us-chipmaking-165-billion-investment-set-to-reshape-tech-jobs">up to $165 billion</a> when the Trump administration threatened higher taxes and steep tariffs.
Read Also: <a href="https://www.benzinga.com/25/05/45519270/nvidia-and-google-back-ai21-labs-in-300m-series-d-to-build-proprietary-llms-challenging-openai-and-anthropic-in-enterprise-ai">Nvidia And Google Back AI21 Labs In $300M Series D To Build Proprietary LLMs, Challenging OpenAI And Anthropic In Enterprise AI</a>
<h2 class="wp-block-heading">Health, Beer, And Back-To-School</h2>
On the healthcare front, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) are shoring up U.S. pharmaceutical production with <a href="https://benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery">tens of billions</a> earmarked <a href="https://www.benzinga.com/content/44189496/eli-lilly-pours-27b-into-u-s-growth-what-it-means-for-investors">for domestic builds</a>. The move is seen as a strategy to insulate against global shocks.
Even beer and back-to-school aren't left out: Anheuser-Busch Inbev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) is dropping <a href="https://www.anheuser-busch.com/newsroom/anheuser-busch-announces-new-300-million-investment-in-manufacturing-operations-across-the-US">$300 million</a> into U.S. plants, while Cra-Z-Art is <a href="https://cra-z-art.com/us-biggest-toy-maker-to-expand-domestic-factories/">scaling up local </a>toy and school supply production. 
For companies like Legacy Precision Molds in Michigan, <a href="https://www.whitehouse.gov/articles/2025/04/american-businesses-rally-behind-president-trumps-tariffs-to-save-manufacturing/">quote activity is heating</a> up thanks to recent tariff tailwinds.
<h2 class="wp-block-heading">Detroit And Beyond</h2>
General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is <a href="https://benzinga.com/startups/25/02/43572782/gm-ceo-on-trumps-trade-threats-we-can-adjust-to-anything-automaker-braces-for-25-tariffs-on-popular-cars-made-in-mexico-and-canada">boosting pickup truck production</a> in Indiana and hiring hundreds, signaling a blue-collar rebound driven by reshoring momentum. 
With manufacturing incentives rising and geopolitics in flux, more firms are likely to follow.
The message? Corporate America isn't just hedging—it's anchoring. Whether for security, politics, or PR, the reshoring wave is in motion.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45517783/magnificent-7-stun-the-street-with-the-best-earnings-beat-since-2021">Magnificent 7 Stun The Street With Best Earnings Beat Since 2021</a></li>
</ul>
Image: Shutterstock

Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Again

Deep-pocketed investors have adopted a bullish approach towards Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JNJ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Johnson &amp; Johnson. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 45% bearish. Among these notable options, 6 are puts, totaling $391,310, and 5 are calls, amounting to $251,653.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $165.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Johnson &amp; Johnson stands at 795.6, with a total volume reaching 5,482.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Johnson &amp; Johnson, situated within the strike price corridor from $150.0 to $165.0, throughout the last 30 days.
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747677685_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$14.55</td>
<td>$14.35</td>
<td>$14.35</td>
<td>$165.00</td>
<td>$119.1K</td>
<td>2.5K</td>
<td>83</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$5.05</td>
<td>$4.65</td>
<td>$4.65</td>
<td>$150.00</td>
<td>$93.0K</td>
<td>136</td>
<td>206</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$10.7</td>
<td>$10.0</td>
<td>$10.6</td>
<td>$160.00</td>
<td>$91.1K</td>
<td>123</td>
<td>86</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/23/25</td>
<td>$0.82</td>
<td>$0.81</td>
<td>$0.81</td>
<td>$150.00</td>
<td>$81.1K</td>
<td>1.4K</td>
<td>3.2K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$0.78</td>
<td>$0.75</td>
<td>$0.78</td>
<td>$155.00</td>
<td>$53.5K</td>
<td>643</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Johnson &amp; Johnson Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,885,401, the JNJ's price is up by 0.28%, now at $151.75. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 58 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $153.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Leerink Partners has revised its rating downward to Market Perform, adjusting the price target to $153. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Market Whales and Their Recent Bets on JNJ Options

Reported Sunday, Innovative Health Secures Landmark $147M Verdict Against J&J Unit Over Anti-Competitive Tactics Targeting Reprocessed Medical Devices

The U.S. and China agreed to de-escalate their trade war by cutting tariffs by 115 percentage points, bringing U.S. duties on Chinese <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">goods down to 30%.</a>
The announcement sparked a broad-based equity rally, with the S&amp;P 500 climbing back to early March 2025 levels and erasing losses from President Donald Trump's &#8220;<a href="https://www.benzinga.com/government/regulations/25/05/45355655/magnificent-seven-gain-700b-after-us-china-slash-tariffs-gold-crashes-whats-driving-markets-monday">Liberation Day&#8221; tariff shock.</a>
The improved trade outlook also prompted economists to cut recession odds and upgrade U.S. growth forecasts for the second half of the year.
<h3 class="wp-block-heading">S&amp;P 500 Logs 5 Consecutive Winning Sessions</h3>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed 5% higher for the week, notching five straight sessions in the green.
Semiconductors kept powering higher. The iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>) rose nearly 10% on the week, logging its fourth straight week of gains and delivering its best monthly rally since 2020.
Yet, clean energy stocks – as tracked by the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) – outshined even chipmakers. Solar names surged after Republicans released a better-than-expected tax proposal <a href="https://www.benzinga.com/top-stories/25/05/45381191/first-solar-eyes-best-2-day-rally-since-2013-after-gop-tax-plan-spares-key-clean-energy-credits">on renewable energy credits.</a> Shares of First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) soared 27% for the week, leading the sector.
<h3 class="wp-block-heading">Trump&#8217;s Middle East Blitz Attracts $2 Trillion In Gulf Commitments</h3>
During his Middle East visit, President Trump secured around $2 trillion in trade and investment pledges from Gulf countries.
<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets-will-go-a-lot-higher">Saudi Arabia committed $600 billion</a> in deals involving Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Oracle Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NASDAQ">ORCL</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Uber Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NASDAQ">UBER</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
<a href="https://www.benzinga.com/government/regulations/25/05/45446924/trump-secures-12-trillion-qatar-deal-as-boeing-ge-land-record-orders">Qatar followed with a $1.2 trillion package</a> focused on energy and infrastructure, inking major contracts with GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) and Boeing.
The United Arab Emirates signed a $200 billion deal to import over one million AI chips from Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and other initiatives with Exxon Mobil Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NASDAQ">XOM</a>), Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
<h3 class="wp-block-heading">UNH In Free Fall, Consumer Inflation Concerns Hit 1980s Levels</h3>
Back on Wall Street, one corporate giant is facing deep losses in what's shaping up to be one of the worst crises in its history. UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares nosedived 27% this week, marking the company&#8217;s worst weekly performance since the 2009 financial crisis and extending a five-week losing streak.
CEO Andrew Witty resigned Tuesday citing "personal reasons," while the company suspended 2025 guidance due <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance">to surging medical costs</a>. A U.S. Department of Justice criminal probe into alleged fraud in its Medicare Advantage <a href="https://www.benzinga.com/general/health-care/25/05/45426769/unitedhealth-stock-plunges-over-8-in-after-hours-trading-as-doj-criminal-probe-adds-to-turmoil-after-ceo-shake-up">program worsened investor fears.</a>
On the macro front, <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45374267/inflation-eases-in-april-as-trumps-tariffs-dont-push-prices-higher">April inflation data</a> signaled softening price pressures, but retail sales dropped, reflecting consumer <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">caution amid trade uncertainty</a>. Inflation expectations are also heating up again.
The <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45470155/consumer-sentiment-crashes-to-5-year-lows-as-inflation-fears-reach-1981-levels">University of Michigan's survey</a> showed the weakest sentiment since 2020 as the one-year consumer inflation outlook hit levels last seen in 1981.
<h3 class="wp-block-heading">Chart Of The Week: Year-Ahead Consumer Inflation Expectations Have Never Been This High Since Early &#8217;80s</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16155140/image-213-1024x529.png" alt="" class="wp-image-918486" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16155140/image-213-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16155140/image-213-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16155140/image-213-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16155140/image-213-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16155140/image-213-2048x1058.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45466937/us-targets-european-digital-rules-in-free-speech-campaign-defending-american-big-tech">US Slams Europe&#8217;s Digital Laws, Calls Them A Danger To Free Expression And American Big Tech </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Sector ETFs

Econ #s

Economics

Federal Reserve

ETFs

FSLR

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

UBER

US-China Trade Truce, Trump's Middle East Deals Spark Wall Street Rally: This Week In Markets

<a href="https://www.gov.uk/government/news/mhra-approves-guselkumab-for-crohns-disease-and-ulcerative-colitis#:~:text=The%20Medicines%20and%20Healthcare%20products,plaque%20psoriasis%20and%20psoriatic%20arthritis.">https://www.gov.uk/government/news/mhra-approves-guselkumab-for-crohns-disease-and-ulcerative-colitis#:~:text=The%20Medicines%20and%20Healthcare%20products,plaque%20psoriasis%20and%20psoriatic%20arthritis.</a>
&nbsp;
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 May 2025, approved guselkumab (Tremfya) to treat Crohn's disease and ulcerative colitis (UC).
Guselkumab is currently approved to treat plaque psoriasis and psoriatic arthritis. However, clinical studies have shown that guselkumab is also efficacious in treating adults with moderately to severely active Crohn's disease and UC who have not responded well to other treatments or experienced unacceptable side effects.
Using guselkumab in Crohn's disease can benefit patients by reducing the signs and symptoms of the disease, which can include diarrhoea and abdominal pain. In UC it helps to reduce abdominal pain and inflammation of the intestinal lining. These effects can improve a patient's ability to do normal daily activities and reduce fatigue.
Guselkumab can be administered either by intravenous infusion or injection for the initial treatment of Crohn's disease. For UC, initial treatment will be administered via an intravenous infusion.

Global

'MHRA Approves Guselkumab For Crohn's Disease And Ulcerative Colitis'

Press Releases

Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

FDA Panel Reiterates the Cancer Risks of Talc

Jessica Dean Named to National Law Journal's 2025 Elite Women of the Plaintiffs Bar

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

RBC Capital

Leerink Partners

Barclays

Raymond James

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
09:45 AMMay 07, 2025	CALL	$150.00	Jun 20, 2025	10	3000	750	123	2438	TRADE	BULLISH
09:45 AMMay 07, 2025	CALL	$150.00	Jun 20, 2025	10	1500	750	62	2438	TRADE	BULLISH
09:44 AMMay 07, 2025	CALL	$150.00	Jun 20, 2025	10	750	750	31	2438	TRADE	BULLISH
09:35 AMMay 07, 2025	CALL	$150.00	Jun 20, 2025	10	750	750	31	2438	TRADE	BULLISH